Novel B cell therapeutic targets in transplantation and immune-mediated glomerular diseases.
B cells and antibodies play an important role in the alloresponse to renal grafts as well as in immune-mediated glomerular diseases. In transplantation, greater recognition and improved diagnosis of antibody-mediated rejection have been a catalyst to the introduction of newer drugs and regimens that target B cells, plasma cells, and donor-specific antibodies to improve the outcome associated with antibody-mediated rejection. In immune-mediated renal disease, novel and more selective B cell therapies are gradually modifying the traditional therapeutic approach that consists of steroids and other immunosuppressants. A new era of selective and more effective immunosuppression agents that target the humoral response is finally emerging in transplantation and renal diseases.
Vincenti
Flavio
F
University of California, San Francisco, Kidney Transplant Service, 505 Parnassus Avenue, M884, San Francisco, CA 94143-0780, USA. flavio.vincenti@ucsfmedctr.org
Cohen
Scott D
SD
Appel
Gerald
G
D001327:Autoimmune Diseases / Q000188:drug therapy*; D001402:B-Lymphocytes / Q000187:drug effects*; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology* / Q000276:immunology; D007678:Kidney Glomerulus; D016030:Kidney Transplantation / Q000009:adverse effects*